Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome. (2022). Archives of Clinical and Medical Case Reports, 6(5), 660-668. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22670